Taylor Morrison Home
TMHC
D.R. Horton
DHI
Adobe
ADBE
Meritage Homes
MTH
Meta Platforms
META
US Stock MarketDetailed Quotes
INCY Incyte
- 60.580
- +0.240+0.40%
Close Mar 20 16:00 ET
- 60.580
- 0.0000.00%
Post 16:46 ET
11.72BMarket Cap403.87P/E (TTM)
61.745High60.210Low2.32MVolume60.260Open60.340Pre Close140.88MTurnover1.44%Turnover Ratio403.87P/E (Static)193.52MShares83.95052wk High3.40P/B9.77BFloat Cap50.35052wk Low--Dividend TTM161.32MShs Float153.150Historical High--Div YieldTTM2.54%Amplitude1.850Historical Low60.695Avg Price1Lot Size
About Incyte Company
Incyte Corp. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of proprietary therapeutics. It focuses on hematology and oncology, and inflammation and autoimmunity therapeutic areas. The company was founded on April 8, 1991 and is headquartered in Wilmington, DE.
Company Profile
SymbolINCY
Company NameIncyte
Listing DateNov 4, 1993
Issue Price7.50
Founded1991
CEOMr. Herve Hoppenot
MarketNASDAQ
Employees2617
Fiscal Year Ends12-31
Address1801 Augustine Cut-Off
CityWilmington
ProvinceDelaware
CountryUnited States of America
Zip Code19803
Phone1-302-498-6700
Websitehttp://www.incyte.com
Company Executives
- Name
- Position
- Salary
- Herve Hoppenot
- Chairman of the Board, President and Chief Executive Officer
- 16.66M
- Thomas Tray
- Vice President and Chief Accounting Officer
- --
- Christiana Stamoulis, M.B.A.
- Executive Vice President and Chief Financial Officer
- 5.08M
- Dr. Steven H. Stein, M.D.
- Executive Vice President and Chief Medical Officer
- 5.63M
- Matteo Trotta
- Executive Vice President and General Manager, Dermatology US
- --
- Barry P. Flannelly, Pharm.D.
- Executive Vice President and General Manager, North America
- 4.09M
- Lee Heeson
- Executive Vice President, Incyte International
- --
- Sheila A Denton
- Executive Vice President, General Counsel and Corporate Secretary
- --
- Michael James Morrissey
- Executive Vice President and Head of Global Technical Operations
- --
- Mohamed Khairie Issa
- Executive Vice President and Head of US Oncology
- --
- Paula J. Swain
- Executive Vice President, Human Resources
- --
- Vijay K. Iyengar
- Executive Vice President, Global Strategy and Corporate Development
- --
- Dr. Pablo J. Cagnoni, M.D.
- President and Head of Research and Development
- 15.83M
- Dr. Katherine A. High, M.D.
- Independent Director
- 454.76K
- Dr. Jacqualyn A. Fouse, PhD
- Independent Director
- 466.26K
- Jean-Jacques Bienaime
- Independent Director
- 478.76K
- Dr. Otis W. Brawley,M.D.
- Independent Director
- 454.76K
- Julian C. Baker
- Lead Independent Director
- 512.76K
- Dr. Edmund P. Harrigan, M.D.
- Independent Director
- 482.26K
- Paul J. Clancy
- Independent Director
- 479.76K
- Dr. Susanne Schaffert, PhD
- Independent Director
- 444.76K
Market Insights
Fed Rate Cut Beneficiaries Fed Rate Cut Beneficiaries
Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data. Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data.
